Literature DB >> 9602687

Differential expression of CD44v6 in metastases of intestinal and diffuse types of gastric carcinoma.

E M Castellà1, A Ariza, I Pellicer, A Fernández-Vasalo, I Ojanguren.   

Abstract

AIMS: To assess whether standard and variant isoforms of CD44 (CD44s, CD44v5, and CD44v6) have a differential expression profile in early versus advanced gastric adenocarcinoma of the diffuse and intestinal types and their metastases.
METHODS: Immunohistochemical expression of CD44s, CD44v5, and CD44v6 was evaluated in 14 early gastric cancers (nine intestinal and five diffuse) and 37 advanced adenocarcinomas (21 intestinal and 16 diffuse) as well as in 18 cases of perigastric lymph node metastasis. Ten normal and five metaplastic gastric mucosa samples were also included in the study.
RESULTS: Although no significant association was found between the degree of invasion and the CD44 expression profile, CD44v6 positivity was detected more frequently in metastases of intestinal-type carcinomas (66%) than in metastases of diffuse-type neoplasms (11%) (p < 0.05). Weak CD44s, CD44v5, and CD44v6 expression was observed focally in both normal and metaplastic gastric mucosa samples.
CONCLUSIONS: These data suggest that CD44v6 expression may be involved in the production of lymph node metastases in intestinal-type gastric carcinoma but not in the diffuse-type disease, the metastatic potential of which is most likely unrelated to the CD44 family of adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9602687      PMCID: PMC500508          DOI: 10.1136/jcp.51.2.134

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  16 in total

Review 1.  CD44 splice variants: metastases meet lymphocytes.

Authors:  P Herrlich; M Zöller; S T Pals; H Ponta
Journal:  Immunol Today       Date:  1993-08

Review 2.  CD44 and its interaction with extracellular matrix.

Authors:  J Lesley; R Hyman; P W Kincade
Journal:  Adv Immunol       Date:  1993       Impact factor: 3.543

3.  CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines.

Authors:  M Hofmann; W Rudy; M Zöller; C Tölg; H Ponta; P Herrlich; U Günthert
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

4.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.

Authors:  U Günthert; M Hofmann; W Rudy; S Reber; M Zöller; I Haussmann; S Matzku; A Wenzel; H Ponta; P Herrlich
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

5.  Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa.

Authors:  K H Heider; J Dämmrich; P Skroch-Angel; H K Müller-Hermelink; H P Vollmers; P Herrlich; H Ponta
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

6.  De-novo expression of CD44 and survival in gastric cancer.

Authors:  B Mayer; K W Jauch; U Günthert; C G Figdor; F W Schildberg; I Funke; J P Johnson
Journal:  Lancet       Date:  1993-10-23       Impact factor: 79.321

7.  Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression.

Authors:  V J Wielenga; K H Heider; G J Offerhaus; G R Adolf; F M van den Berg; H Ponta; P Herrlich; S T Pals
Journal:  Cancer Res       Date:  1993-10-15       Impact factor: 12.701

8.  Importance of different CD44v6 expression in human gastric intestinal and diffuse type cancers for metastatic lymphogenic spreading.

Authors:  J Dämmrich; H P Vollmers; K H Heider; H K Müller-Hermelink
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

9.  Major histocompatibility complex-specific recognition of Mls-1 is mediated by multiple elements of the T cell receptor.

Authors:  D L Woodland; H P Smith; S Surman; P Le; R Wen; M A Blackman
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

10.  Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types.

Authors:  L J Picker; M Nakache; E C Butcher
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

View more
  7 in total

1.  Effect of P-selectin monoclonal antibody on metastasis of gastric cancer and immune function.

Authors:  Jin-Lian Chen; Wei-Xiong Chen; Jin-Shui Zhu; Ni-Wei Chen; Tong Zhou; Ming Yao; Dong-Qing Zhang; Yun-Lin Wu
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

2.  Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance.

Authors:  Kamran Ghaffarzadehgan; Mostafa Jafarzadeh; Hamid Reza Raziee; Hamid Reza Sima; Ehsan Esmaili-Shandiz; Hanieh Hosseinnezhad; Ali Taghizadeh-Kermani; Omeed Moaven; Maryam Bahrani
Journal:  World J Gastroenterol       Date:  2008-11-07       Impact factor: 5.742

3.  Sequential expression of putative stem cell markers in gastric carcinogenesis.

Authors:  T Wang; C W Ong; J Shi; S Srivastava; B Yan; C L Cheng; W P Yong; S L Chan; K G Yeoh; B Iacopetta; M Salto-Tellez
Journal:  Br J Cancer       Date:  2011-08-09       Impact factor: 7.640

Review 4.  The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer.

Authors:  Ranjeeta Thapa; George D Wilson
Journal:  Stem Cells Int       Date:  2016-04-21       Impact factor: 5.443

5.  Nomogram Incorporating CD44v6 and Clinicopathological Factors to Predict Lymph Node Metastasis for Early Gastric Cancer.

Authors:  Bang Wool Eom; Jungnam Joo; Boram Park; Min Jung Jo; Seung Ho Choi; Soo-Jeong Cho; Keun Won Ryu; Young-Woo Kim; Myeong-Cherl Kook
Journal:  PLoS One       Date:  2016-08-02       Impact factor: 3.240

6.  Prognostic Value of Cancer Stem Cell Markers CD44 and ALDH1/2 in Gastric Cancer Cases

Authors:  Fatma Senel; Tuba Dilay Kökenek Unal; Hatice Karaman; Mevlüde Inanç; Aynur Aytekin
Journal:  Asian Pac J Cancer Prev       Date:  2017-09-27

Review 7.  CD44 In Sarcomas: A Comprehensive Review and Future Perspectives.

Authors:  Enrique Fernández-Tabanera; Raquel M Melero-Fernández de Mera; Javier Alonso
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.